Comparative Efficacy of BTK Inhibitors in Treatment-Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis.

J Cell Mol MedSep 1, 2026
Clinical ResearchHematologyOncology (Medical)Open access

Fangfei Xu, Xiuping Zou, Yulin Yang et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy of Bruton tyrosine kinase inhibitors (BTKis) in treatment-naïve and relapsed/refractory mantle cell lymphoma (MCL). Among 70 studies, the complete response (CR) rate was significantly higher in treatment-naïve patients (76.5%) compared to relapsed/refractory patients (43.2%). Zanubrutinib showed a CR rate of 95.2% in treatment-naïve patients, outperforming acalabrutinib and ibrutinib.

Key findings

  • The CR rate in treatment-naïve patients was 76.5% vs 43.2% in relapsed/refractory patients.
  • Zanubrutinib achieved a CR rate of 95.2%, significantly higher than acalabrutinib or ibrutinib (p=0.0042).
  • In the relapsed/refractory group, the combination therapy had a CR rate of 68.3% (p<0.0001).
  • Acalabrutinib had a higher CR rate of 43.2% compared to zanubrutinib or ibrutinib in monotherapy.

Why it matters

The findings highlight the potential of BTK inhibitors, particularly zanubrutinib and acalabrutinib, in improving response rates in mantle cell lymphoma, which may influence treatment decisions and guidelines.

Source

PubMed · PMID 42687221Free full text on PubMed Central

Published in J Cell Mol Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchOncology (Medical)

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

This phase 3 randomized clinical trial evaluated the efficacy and safety of osimertinib combined with chemotherapy versus osimertinib alone in 294 patients with advanced non-small cell lung cancer (NSCLC) harboring…

JAMASep 8, 2026Open accessRead summary
Clinical ResearchHematology

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

This phase 2 randomized trial compared azacitidine plus venetoclax to induction chemotherapy in 172 previously untreated adults with acute myeloid leukemia (AML) eligible for induction.

N Engl J MedSep 3, 2026Read summary
Clinical ResearchPsychiatry

The efficacy of modified psychodynamic psychotherapy for patients with schizophrenia-spectrum disorders in Germany: a prospective, single-centre, assessor-blinded, parallel-group, randomised controlled trial.

This randomized controlled trial evaluated the efficacy of Modified Psychodynamic Psychotherapy for Schizophrenia (MPP-S) combined with treatment as usual (TAU) in 130 outpatients with schizophrenia-spectrum disorders…

Lancet PsychiatrySep 10, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.